If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine.

Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.

Aug 4 (Reuters) - Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against ...

Moderna (NasdaqGS:MRNA) has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine targeting ...

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine set to target the Bundibugyo strain, which is currently ...

Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.

The program is backed by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million.

Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.

The Phase 1 trial of the mRNA vaccine candidate will assess safety, determine the dosage range and identify potential side ...

The vaccine relies on the same mRNA technology used in Moderna’s Covid-19 vaccine. Read more at straitstimes.com. Read more ...

Moderna has launched the world's first Phase 1 trial of a Bundibugyo Ebola mRNA vaccine, targeting an Ebola strain that still ...